A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 31, 2001

Study Completion Date

December 31, 2003

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

OSI-461

Trial Locations (15)

24101

Oncology & Hematology Associates of Southwest Virginia, Roanoke

27103

Piedmont Hem Onc Assoc, P.A., Winston-Salem

29615

Cancer Centers of the Carolinas, Greenville

32207

Florida Oncology Associates, Jacksonville

34474

Ocala Oncology Center, Ocala

45439

Dayton Oncology/Hematology Consultants, Dayton

52403

Iowa Oncology Associates, Cedar Rapids

64111

Oncology/Hematology Associates of Kansas City, Kansas City

75702

Tyler Cancer Center, Tyler

78229

Hematology Oncology Associates of South Texas, San Antonio

78705

Southwest Regional Cancer Center, Austin

80012

Rocky Mountain Cancer Centers, Aurora

85012

Arizona Hematology & Oncology Associates, Phoenix

97401

Willamette Valley Cancer Center, Eugene

99202

Cancer Care Northwest, Spokane

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

OSI Pharmaceuticals

INDUSTRY

lead

Astellas Pharma Inc

INDUSTRY

NCT00073489 - A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL) | Biotech Hunter | Biotech Hunter